Michael Vance Jensen

US Patent:

6410319, Jun 25, 2002

Filed:

Oct 20, 1999

Appl. No.:

09/421295

Inventors:

Andrew Raubitschek - San Marino CA
Anna Wu - Sherman Oaks CA
Michael C. Jensen - Pasadena CA

Assignee:

City of Hope - Duarte CA

International Classification:

C12N 506

US Classification:

4353431, 4353201, 435325, 435326, 435328, 435332, 435343, 435344, 435372, 4353722, 4353723, 536 231, 536 234

Abstract:

Genetically engineered, CD20-specific redirected T cells expressing a cell surface protein-having an extracellular domain comprising a receptor which is specific for CD20, an intracellular signaling domain, and a transmembrane domain. Use of such cells for cellular immunotherapy of CD20 malignancies and for abrogating any untoward B cell function. In one embodiment, the cell surface protein is a single chain FvFc: receptor where Fv designates the V and V chains of a single chain monoclonal antibody to CD20 linked by peptide, Fc represents a hinge-CH -CH region of a human IgG , and represents the intracellular signaling domain of the zeta chain of human CD3. A method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor.

US Patent:

7070995, Jul 4, 2006

Filed:

Apr 11, 2002

Appl. No.:

10/120198

Inventors:

Michael Jensen - Pasadena CA, US

Assignee:

City of Hope - Duarte CA

International Classification:

C12N 15/85
C12N 15/86
C07K 16/00

US Classification:

4353723, 435325, 435328, 435344, 4353441, 435372, 5303873, 5303888, 53038885

Abstract:

Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular signaling domain, and a transmembrane domain, and methods of use for such cells for cellular immunotherapy of CE7+ neuroblastoma are disclosed. In one embodiment, the immune cell is a T cell and the cell surface protein is a single chain FvFc:ζ receptor where Fv designates the Vand Vchains of a single chain monoclonal antibody to CE7 linked by peptide, Fc represents a hinge —C2—C3 region of a human IgG, and ζ represents the intracellular signaling domain of the zeta chain of human CD3. DNA constructs encoding a chimeric T-cell receptor and a method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor are also disclosed.

US Patent:

7265209, Sep 4, 2007

Filed:

Jun 30, 2006

Appl. No.:

11/477572

Inventors:

Michael Jensen - Pasadena CA, US

Assignee:

City of Hope - Duarte CA

International Classification:

C12P 21/08
C07K 16/00
C12N 5/06
C12N 5/08
C12P 21/04
A61K 39/395

US Classification:

5303873, 53038822, 5303888, 53038885, 435328, 4353441, 435372, 4353723, 4241341, 4241351, 4241431, 4241551

Abstract:

Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular signaling domain, and a transmembrane domain, and methods of use for such cells for cellular immunotherapy of CE7+ neuroblastoma are disclosed. In one embodiment, the immune cell is a T cell and the cell surface protein is a single chain FvFc: ζ receptor where Fv designates the Vand Vchains of a single chain monoclonal antibody to CE7 linked by peptide, Frepresents a hinge-C2-C3 region of a human IgG, and ζ represents the intracellular signaling domain of the zeta chain of human CD3. DNA constructs encoding a chimeric T-cell receptor and a method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor are also disclosed.

US Patent:

7354762, Apr 8, 2008

Filed:

Sep 4, 2007

Appl. No.:

11/849643

Inventors:

Michael Jensen - Pasadena CA, US

Assignee:

City of Hope - Duarte CA

International Classification:

C12N 5/06
C12N 5/08
C12P 21/06
C12P 21/08
C07K 16/00
A61K 39/395
C07H 21/04

US Classification:

4353723, 4241341, 4241351, 4241431, 4241551, 435 691, 435328, 4353441, 435372, 53038822, 5303888, 53038885

Abstract:

Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular signaling domain, and a transmembrane domain, and methods of use for such cells for cellular immunotherapy of CE7+ neuroblastoma are disclosed. In one embodiment, the immune cell is a T cell and the cell surface protein is a single chain FvFc:ζ receptor where Fv designates the Vand Vchains of a single chain monoclonal antibody to CE7 linked by peptide, Fc represents a hinge-C2-C3 region of a human IgG, and ζ represents the intracellular signaling domain of the zeta chain of human CD3. DNA constructs encoding a chimeric T-cell receptor and a method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor are also disclosed.

US Patent:

7446191, Nov 4, 2008

Filed:

Feb 8, 2008

Appl. No.:

12/028442

Inventors:

Michael Jensen - Pasadena CA, US

Assignee:

City of Hope - Duarte CA

International Classification:

C07H 21/04
C12N 15/09
A61K 39/395
C12P 21/04
C12P 21/08
C12N 7/00
C12N 5/06
C12N 5/08

US Classification:

536 234, 536 2353, 4241341, 4241351, 4241431, 4241551, 435 696, 435 697, 4352351, 4353201, 435328, 4353441, 435372, 4353723, 5303873, 53038822, 53038885

Abstract:

Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular signaling domain, and a transmembrane domain, and methods of use for such cells for cellular immunotherapy of CE7 neuroblastoma are disclosed. In one embodiment, the immune cell is a T cell and the cell surface protein is a single chain FvFc: receptor where Fv designates the Vand Vchains of a single chain monoclonal antibody to CE7 linked by peptide, Fc represents a hinge-C2-C3 region of a human IgG, and represents the intracellular signaling domain of the zeta chain of human CD3. DNA constructs encoding a chimeric T-cell receptor and a method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor are also disclosed.

US Patent:

7514537, Apr 7, 2009

Filed:

Nov 16, 2005

Appl. No.:

11/274344

Inventors:

Michael Jensen - Sierra Madre CA, US

Assignee:

City of Hope - Duarte CA

International Classification:

C07K 16/46
C12N 5/22
C12N 15/63

US Classification:

5303873, 424 9321, 4353201, 4353723, 530350

Abstract:

The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signaling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin/paracrine cytokine systems utilized by human maligancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targeting domain of the IL-13Rα2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain.

US Patent:

7747464, Jun 29, 2010

Filed:

Jul 8, 2004

Appl. No.:

10/710413

Inventors:

Michael E. Jensen - Santa Ana CA, US

International Classification:

G06Q 30/00
G05B 19/418

US Classification:

705 1435, 725110, 705 8

Abstract:

A method of promoting and playing a motion picture at a theater in which the motion picture is not scheduled to begin at any particular time, the patron may visit the theater when convenient, and the motion picture begins a pre-determined period of time after the first patron arrives. The motion picture may begin earlier if a pre-determine level of patrons arrive. Various system are also described to support this process, including systems that delay the determination of the motion picture that will be played by a particular theater until after a visiting patron selects that motion picture. Applying these concepts to purchased or rented offices, apartments and condominiums is also disclosed.

US Patent:

8324353, Dec 4, 2012

Filed:

Mar 11, 2011

Appl. No.:

13/046518

Inventors:

Michael Jensen - Sierra Madre CA, US

Assignee:

City of Hope - Durate CA

International Classification:

C07K 16/46
C07K 19/00
C12N 5/0783
C12N 5/22
C12N 15/63

US Classification:

5303873, 424 9321, 435 697, 4353201, 4353723, 530350

Abstract:

The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin/paracrine cytokine systems utilized by human maligancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targeting domain of the IL-13Rα2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain.